Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it will host a key opinion leader webcast on the current and future HCC (primary liver cancer) treatment landscape, including how treatment challenges and needs in HCC differs from most other cancers. The webcast will take place on September 8, 2023 at 13:00 CET/07:00 EST.
The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC. He will be joined by Dr. Maria Reig, Liver Cancer Unit, Hospital Clínic BCLC group, Villarroel, Barcelona, Spain, who will discuss how HCC is different from many other tumor types and its unique treatment challenges. Both Drs are investigators in the phase 1b/2a study with fostrox in combination with Lenvima and will also share their perspectives from the ongoing study. They will be joined by Dr Pia Baumann, Medivir’s CMO who will provide an update on the ongoing study and fostrox development plans.
All three will be available to answer questions following the formal presentations.
The webcast will be streamed via a link on the website: www.medivir.com/investors/presentations The presentation will be available on Medivir´s website after the webcast.
- “The promising observations we have seen so far in the ongoing phase 1b/2a study of fostrox in combination with Lenvima mean that we are further intensifying our plans for the next phase of clinical development of fostrox. When doing so, it is critical that this is done in close collaboration with external experts to ensure that the specific needs of the disease and changes in treatment landscape are central components of future plans. We are pleased that Drs Evans and Reig, members of our Scientific Advisory Council, are able to provide their expertise on these important topics in this webcast,” says Dr. Pia Baumann, CMO at Medivir.
Dr. Jeff Evans is a Professor of Translational Cancer Research in the School of Cancer Sciences, University of Glasgow, and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre, Glasgow, UK. He is the Lead of the Glasgow Experimental Cancer Medicine Centre (ECMC) and National Clinical Lead of the NHS Scotland Cancer Research Network. He is an investigator in the fostrox clinical development program.
Dr. Maria Reig is the Head of the BCLC and Liver Oncology Unit at Hospital Clinic of Barcelona in Spain. Her expertise and area of interest is the development of prognostic models for patients with liver cancer and evaluation of treatment options with special emphasis in systemic therapy as well as new research about immune modulation and cancer emergence after antiviral treatment. She is an investigator in the fostrox clinical program.